Abstract
Second generation antipsychotics (SGAs) are approved by the US Food and Drug Administration for treatment of schizophrenia, bipolar disorder, and refractory depression. Since the 1990’s, antipsychotic prescription has more than doubled, with off-label use disproportionately contributing. SGAs used “on-label’ have significant metabolic adverse effects (MAEs). Currently, there is no literature systematically investigating the MAEs of ‘off-label’ use to guide clinical decision-making practices.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
